FDA licenses GERD treatment

Published: 28-May-2001


AHP's iv formulation of pantoprazole sodium (Protonix) has been approved by the US FDA for the short-term treatment of gastrooesophageal reflux disease, as an alternative to oral therapy in patients unable to continue taking the extended release tablet formulation. It is the first proton pump inhibitor to be made available in the US for both iv and oral use.

You may also like